NASDAQ
GOVX
Last Price
US $1.05
KEY FIGURES
MKT CAP
$1.0M
EPS
TTM
$-10.64
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
2.47x
YIELD
0.00%
GROWTH
Revenue Y/Y
6.42%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $1.05
129921882.86%
Default assumptions
EBITDA Multiple
Fair Value
Market $1.05
210535945.71%
Default assumptions
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
GeoVax Labs, Inc. cash flow to debt ratio of -2.55K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
GeoVax Labs, Inc.'s free cash flow has increased -12.94% from $-24.70M last year to $-21.50M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
GeoVax Labs, Inc.'s debt to equity ratio is 0.80, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
GeoVax Labs, Inc. has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
GeoVax Labs, Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
GeoVax Labs, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
GeoVax Labs, Inc.'s profit margin has decreased (296.73%) in the last year from -631.98% to -2.51K%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
GeoVax Labs, Inc.'s short-term assets of $5.31M exceed its short-term liabilities of $1.94M
Decreasing performance - ROA.
GeoVax Labs, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
GeoVax Labs, Inc.'s return on equity of -709.51%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
GeoVax Labs, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
GeoVax Labs, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
GeoVax Labs, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
GeoVax Labs, Inc. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
GeoVax Labs, Inc.'s yearly earnings has increased -14.11% since last year from $-24.99M to $-21.46M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
GeoVax Labs, Inc.'s yearly revenue has decreased -37.06% since last year from $3.95M to $2.49M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -2.42K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
GeoVax Labs, Inc.'s 3-year revenue CAGR of 212.55% is positive, indicating growing revenue over the past 3 years
Decreasing performance - Revenue consistency.
GeoVax Labs, Inc. had revenue growth in only 1.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
GeoVax Labs, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Undervalued - DCF valuation.
GeoVax Labs, Inc. is undervalued relative to its fair value price of 1.36M based on Discounted Cash Flow model
Overvalued - Earnings yield.
GeoVax Labs, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - EBITDA valuation.
GeoVax Labs, Inc. is undervalued relative to its fair value price of 2.21M based on EBITDA multiple model
Overvalued - EV/EBITDA.
GeoVax Labs, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
GeoVax Labs, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
GeoVax Labs, Inc. has a price-to-book ratio of 4.27x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
GeoVax Labs, Inc. has a price-to-sales ratio of 2.47x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-709.51%
Return on equity
ROIC: -2421%
Valuation History
-0.05X
Price to Earnings
EV/EBITDA: -0.01X
Cash flow
Profit margin
-33.44%
(FY vs FY)
Cash flow Y/Y
-32.98%
(FY vs FY)
Base valuations use default assumptions. Customize in the Valuator.